Saw Palmetto Prostate Randomized Trial Evidence Table

Structured evidence table for Saw Palmetto Prostate Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Saw Palmetto Prostate Randomized TrialThen, in a randomized controlled trial (RCT), Kucuk et al found that acupuncture was more effective than pharmacotherapy (levofloxacin and ibuprofen) in relieving symptoms associated with prostatitis.Zhou et al compared the clinical efficacy of 2 types of acupuncture (long-needle acupuncture vs traditional acupuncture) in the treatment of CP/CPPS.4Li Debo (2026)Research status and progress of Chinese traditional medicine for chronic prostatitis/chronic pelvic pain syndrome: A bibliometric analysis and literature review
Saw Palmetto Prostate Randomized TrialThe authors found that trigger point injection, as an adjunct to physical therapy, was well-tolerated and resulted in symptom improvement in approximately half of the CP/CPPS patients, although its durability and long-term outcomes have not yet been validated.Furthermore, Honjo et al investigated the efficacy of acupuncture in treating CP with intrarenal pelvic venous congestion.4Li Debo (2026)Research status and progress of Chinese traditional medicine for chronic prostatitis/chronic pelvic pain syndrome: A bibliometric analysis and literature review
Saw Palmetto Prostate Randomized TrialCurrent evidence suggests a potential dose–response relationship between acupuncture treatment sessions and therapeutic outcomes for CP/CPPS.4Li Debo (2026)Research status and progress of Chinese traditional medicine for chronic prostatitis/chronic pelvic pain syndrome: A bibliometric analysis and literature review
Saw Palmetto Prostate Randomized Trial1 [] 2 [] 3 [] 4 5 [,] Chronic prostatitis (CP) ranks among the most challenging clinical conditions encountered in urological practice.4Li Debo (2026)Research status and progress of Chinese traditional medicine for chronic prostatitis/chronic pelvic pain syndrome: A bibliometric analysis and literature review
Saw Palmetto Prostate Randomized TrialLikewise, all the treatments significantly reduced the IPSS scores by 74.2% (Palmex®), 74.6% (saw palmetto), 60.3% (finasteride), and 74.2% (tamsulosin), also decreasing the prostate size and the residual post-voiding volume.4Mederos RG (2025)Comparative Study of the Efficacy and Tolerability of Palmex® (Roystonea regia Lipid Extract), Saw Palmetto, Finasteride and Tamsulosin in Patients with Benign Prostatic Hyperplasia.
Saw Palmetto Prostate Randomized TrialNo significant differences among the groups were found regarding any efficacy variable.4Mederos RG (2025)Comparative Study of the Efficacy and Tolerability of Palmex® (Roystonea regia Lipid Extract), Saw Palmetto, Finasteride and Tamsulosin in Patients with Benign Prostatic Hyperplasia.
Saw Palmetto Prostate Randomized TrialConclusion Palmex® for 6 months demonstrated to have a comparable efficacy to saw palmetto, finasteride, and tamsulosin in patients with mild and moderate BPH, being safe and well tolerated.4Mederos RG (2025)Comparative Study of the Efficacy and Tolerability of Palmex® (Roystonea regia Lipid Extract), Saw Palmetto, Finasteride and Tamsulosin in Patients with Benign Prostatic Hyperplasia.
Saw Palmetto Prostate Randomized TrialObjective Evaluate and compare the efficacy and tolerability of the treatment with Palmex®, saw palmetto, finasteride, or tamsulosin administered for 6 months to patients with benign prostatic hyperplasia (BPH).4Mederos RG (2025)Comparative Study of the Efficacy and Tolerability of Palmex® (Roystonea regia Lipid Extract), Saw Palmetto, Finasteride and Tamsulosin in Patients with Benign Prostatic Hyperplasia.

Source documents

  1. Research status and progress of Chinese traditional medicine for chronic prostatitis/chronic pelvic pain syndrome: A bibliometric analysis and literature review
  2. Comparative Study of the Efficacy and Tolerability of Palmex® (Roystonea regia Lipid Extract), Saw Palmetto, Finasteride and Tamsulosin in Patients with Benign Prostatic Hyperplasia.